Published in:
01-09-2019 | Heart Failure | Editorial
Role of percutaneous edge-to-edge repair in secondary mitral regurgitation after MITRA-FR and COAPT
A comment by the section of AV-valve treatment of the Working Group of Interventional Cardiology (AGIK) of the German Society of Cardiology (DGK)
Authors:
Roman Pfister, J. Hausleiter, P. Boekstegers, H. Möllmann, H. Nef, V. Rudolph, the Working Group of Interventional Cardiology of the German Society of Cardiology
Published in:
Clinical Research in Cardiology
|
Issue 9/2019
Login to get access
Excerpt
Severe secondary mitral regurgitation (MR) affects about one of four patients with heart failure and reduced ejection fraction (HFrEF) and is associated with a twofold increase in mortality and heart failure hospitalization [
1]. Evidence-based medical and device [cardiac resynchronization (CRT)] therapy improves outcome in HFrEF patients, contributes to reverse remodeling and improvement of MR and hence is the gold-standard for treatment of secondary MR in current guidelines [
2]. Until now, evidence was lacking on whether specific treatment of secondary MR, i.e., surgical or interventional valve repair or replacement, can impact the course of HFrEF and patient outcome. Accordingly, current guidelines give only a low class of recommendation for isolated surgical or interventional treatment of secondary MR for patients who are symptomatic despite optimal HFrEF therapy [
2,
3]. MITRA-FR and COAPT are the first randomized controlled trials to examine repair of secondary MR using the percutaneous MitraClip technique in patients with symptomatic HFrEF in addition to the gold-standard of guideline-directed medical and device therapy [
4,
5]. …
